Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5079262 | DUSA | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
Sep, 2013
(10 years ago) | |
US5954703 | DUSA | Method and apparatus for applying 5-aminolevulinic acid |
Oct, 2017
(6 years ago) | |
US8758418 | DUSA | Illuminator for photodynamic therapy |
May, 2018
(5 years ago) | |
US8216289 | DUSA | Illuminator for photodynamic therapy |
May, 2018
(5 years ago) | |
US6709446 | DUSA | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
May, 2018
(5 years ago) | |
US7723910 | DUSA | Method of photodynamically diagnosing or treating a contoured surface |
Jun, 2019
(4 years ago) | |
US11077192 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US11690914 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US10357567 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US11135293 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US11571478 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) |
Levulan is owned by Dusa.
Levulan contains Aminolevulinic Acid Hydrochloride.
Levulan has a total of 11 drug patents out of which 6 drug patents have expired.
Expired drug patents of Levulan are:
Levulan was authorised for market use on 03 December, 1999.
Levulan is available in solution;topical dosage forms.
Levulan can be used as treatment of non-hyperkeratotic actinic keratoses of face and scalp, treatment of actinic keratoses of upper extremities by photodynamic therapy.
The generics of Levulan are possible to be released after 12 January, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-766) | Mar 09, 2021 |
M(M-82) | Mar 12, 2013 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of non-hyperkeratotic actinic keratoses of face and scalp; Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION;TOPICAL